J Korean Med Sci.  2022 Oct;37(38):e301. 10.3346/jkms.2022.37.e301.

The Degree of Glycemic Control for the First Three Months Determines the Next Seven Years

• Lee N
• Kim DJ

• KMID: 2533567
• DOI: http://doi.org/10.3346/jkms.2022.37.e301

Reference

1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1204–1222. PMID: 33069326.

2. Bae JH, Han KD, Ko SH, Yang YS, Choi JH, Choi KM, et al. Diabetes fact sheet in Korea 2021. Diabetes Metab J. 2022; 46(3):417–426. PMID: 35656565.

3. Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care. 2021; 44(10):2231–2237.

4. Caballero AE, Nordstrom BL, Liao B, Fan L, Zhang N, Fraeman KH, et al. Individualized HbA1c target selection and achievement in the Multinational Observational Study Assessing Insulin Use (MOSA1c) type 2 diabetes study. J Diabetes Complications. 2021; 35(11):108011. PMID: 34535360.

5. Kim KJ, Choi J, Bae JH, Kim KJ, Yoo HJ, Seo JA, et al. Time to reach target glycosylated hemoglobin is associated with long-term durable glycemic control and risk of diabetic complications in patients with newly diagnosed type 2 diabetes mellitus: a 6-year observational study. Diabetes Metab J. 2021; 45(3):368–378. PMID: 33081424.

6. Kim H, Jung DY, Lee SH, Cho JH, Yim HW, Kim HS. Long-term changes in HbA1c according to blood glucose control status during the first 3 months after visiting a tertiary university hospital. J Korean Med Sci. 2022; 37(38):e281.

7. Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017; 5(6):431–437. PMID: 28365411.

8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131):837–853. PMID: 9742976.

9. Hanefeld M, Fleischmann H, Siegmund T, Seufert J. Rationale for timely insulin therapy in type 2 diabetes within the framework of individualised treatment: 2020 update. Diabetes Ther. 2020; 11(8):1645–1666. PMID: 32564335.

10. Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019; 394(10208):1519–1529. PMID: 31542292.

11. Andreozzi F, Candido R, Corrao S, Fornengo R, Giancaterini A, Ponzani P, et al. Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review. Diabetol Metab Syndr. 2020; 12(1):52. PMID: 32565924.